FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
Barak Palatchi, CEO of ImPact Biotech, said, “We are delighted to receive Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer, further validating ImPact’s technology and the potential benefits our product could bring to patients with locally advanced Pancreatic Cancer. We continue to believe and follow our strategy, refocusing Padeliporfin VTP treatment on patients with limited treatment options. In Pancreatic Cancer, with limited treatment options for patients who have unresectable locally advanced disease our hope is that Padeliporfin VTP will offer a safe and effective treatment that will render the disease eligible for definitive treatment. Pancreatic Cancer is one of our priority indications within our ambitious plan. We are looking forward to exploring the possibility of offering Padeliporfin VTP to more patients coping with life threatening cancers.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines